Chagas disease in immunocompromised patients
SUMMARYAs Chagas disease remains prevalent in the Americas, it is important that healthcare professionals and researchers are aware of the screening, diagnosis, monitoring, and treatment recommendations for the populations of patients they care for and study. Management of Trypanosoma cruzi infection in immunocompromised hosts is challenging, particularly because, regardless of antitrypanosomal treatment status, immunocompromised patients with Chagas disease are at risk for T. cruzi reactivation, which can be lethal. Evidence-based practices to prevent and manage T. cruzi reactivation vary depending on the type of immunocompromise. Here, we review available data describing Chagas disease epidemiology, testing, and management practices for various populations of immunocompromised individuals, including people with HIV and patients undergoing solid organ and hematopoietic stem cell transplantation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Clinical microbiology reviews - (2024) vom: 28. März, Seite e0009923 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Clark, Eva H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bone marrow transplantation |
|---|
| Anmerkungen: |
Date Revised 28.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1128/cmr.00099-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370357604 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370357604 | ||
| 003 | DE-627 | ||
| 005 | 20240329002753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/cmr.00099-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM370357604 | ||
| 035 | |a (NLM)38546225 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Clark, Eva H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chagas disease in immunocompromised patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a SUMMARYAs Chagas disease remains prevalent in the Americas, it is important that healthcare professionals and researchers are aware of the screening, diagnosis, monitoring, and treatment recommendations for the populations of patients they care for and study. Management of Trypanosoma cruzi infection in immunocompromised hosts is challenging, particularly because, regardless of antitrypanosomal treatment status, immunocompromised patients with Chagas disease are at risk for T. cruzi reactivation, which can be lethal. Evidence-based practices to prevent and manage T. cruzi reactivation vary depending on the type of immunocompromise. Here, we review available data describing Chagas disease epidemiology, testing, and management practices for various populations of immunocompromised individuals, including people with HIV and patients undergoing solid organ and hematopoietic stem cell transplantation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Chagas disease | |
| 650 | 4 | |a Trypanosoma cruzi | |
| 650 | 4 | |a bone marrow transplantation | |
| 650 | 4 | |a human immunodeficiency virus | |
| 650 | 4 | |a immunocompromised hosts | |
| 650 | 4 | |a organ transplantation | |
| 700 | 1 | |a Messenger, Louisa A |e verfasserin |4 aut | |
| 700 | 1 | |a Whitman, Jeffrey D |e verfasserin |4 aut | |
| 700 | 1 | |a Bern, Caryn |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology reviews |d 1996 |g (2024) vom: 28. März, Seite e0009923 |w (DE-627)NLM012914312 |x 1098-6618 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:28 |g month:03 |g pages:e0009923 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/cmr.00099-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 28 |c 03 |h e0009923 | ||